Hypercholesterolemia – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry

$2000
Buy Report

Published: June 05, 2024 Report Code: GDGMDHC23056IDB-L5

Select Item

Empower your strategies with our Hypercholesterolemia – Drugs In Development, 2024 report and make more profitable business decisions.

Hypercholesterolemia is a condition characterized by very high levels of cholesterol in the blood. This leads to the formation of sticky deposits (called plaque) along the artery walls. Plaque can completely block blood flow through an artery, causing a heart attack or stroke. Two forms of the condition exist: heterozygous familial hypercholesterolemia (HeFH) and homozygous familial hypercholesterolemia (HoFH). Risk factors include obesity, family history, high blood pressure, smoking, and diabetes. Treatment includes statins, bile acid sequestrants, fibric acid derivatives, and cholesterol absorption inhibitors.

The Hypercholesterolemia drugs in development market research report provide comprehensive information on the therapeutics under development for Hypercholesterolemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hypercholesterolemia and features dormant and discontinued products.

Note:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Hypercholesterolemia
Key Targets
· Proprotein Convertase Subtilisin/Kexin Type 9; 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase; Angiopoietin Related Protein 3; NPC1 Like Intracellular Cholesterol Transporter 1; Apolipoprotein C III; ATP Citrate Synthase; Cholesteryl Ester Transfer Protein; Thyroid Hormone Receptor Beta; Squalene Synthase; and Low Density Lipoprotein Receptor
Key Mechanisms of Action
· Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor; 3 Hydroxy 3 Methylglutaryl Coenzyme A Reductase Inhibitor; Angiopoietin Related Protein 3 Inhibitor; NPC1 Like Intracellular Cholesterol Transporter 1 Inhibitor; Apolipoprotein C III Inhibitor; ATP Citrate Synthase Inhibitor; Cholesteryl Ester Transfer Protein Inhibitor; Squalene Synthase Inhibitor; Thyroid Hormone Receptor Beta Agonist; and Thyroid Hormone Receptor Agonist
Key Routes of Administration
· Oral; Subcutaneous; Intravenous; Buccal; Intramuscular; Intraperitoneal; Nasal; Parenteral; Sublingual; and Topical
Key Molecule Types
· Small Molecule; Monoclonal Antibody; Gene Therapy; Antisense RNAi Oligonucleotide; Antisense Oligonucleotide; Synthetic Peptide; Biologic; Peptide; Fusion Protein; and Conjugate Vaccine
Major Companies
· Verve Therapeutics Inc; Arrowhead Pharmaceuticals Inc; Huons Co Ltd; iMetabolic Biopharma Corp; Nyrada Inc; NewAmsterdam Pharma Company NV; Medlab Clinical Ltd; LipimetiX Development Inc; Imagine Pharma LLC; and Ionis Pharmaceuticals Inc

Scope

  • Therapeutics in Development: Covering 130 molecules, with 118 developed by companies and the rest by universities/institutes.

  • Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.

  • Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.

  • Development History: Access the complete research and development history.

  • Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.

Reasons to Buy

  • Holistic insights: Understand the broad spectrum of Hypercholesterolemia therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.

  • Pipeline Exploration: Explore the detailed Hypercholesterolemia pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.

  • Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Hypercholesterolemia treatments for adaptable decision-making.

  • Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.

Key Players

Addpharma Inc
AFFiRiS AG
Ahn-Gook Pharmaceutical Co Ltd
Akeso Inc
Alexion Pharmaceuticals Inc
Amgen Inc
Amytrx Therapeutics Inc
Arrowhead Pharmaceuticals Inc
Astellas Pharma Inc
AstraZeneca Plc
Beijing Mabworks Biotech Co Ltd
BioLingus AG
Bojiyuan (Shanghai) Biopharmaceutical Co Ltd
Boryung Pharmaceutical Co Ltd
CardioPharma Inc
Celltrion Inc
Centeer BioTherapeutics Ltd Co
Chiesi Farmaceutici SpA
Cholesgen Shanghai Co Ltd
Chong Kun Dang Pharmaceutical Corp.
Civi Biopharma Inc
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
Daewon Pharmaceutical Co Ltd
Daewoong Pharmaceutical Co Ltd
Dalian Wista Pharmaceutical Co Ltd
Delivra Corp
Draupnir Bio Aps
EDIRNA Inc
Eight Plus One Pharmaceutical Co Ltd
EmendoBio Inc
Epicrispr Biotechnologies Inc
Esperion Therapeutics Inc
Federal University of Rio de Janeiro
Golden Biotechnology Corp
Gruthan Bioscience LLC
Guangzhou Jiayue Pharmaceutical Technology Co Ltd
Haisco Pharmaceutical Group Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hanmi Science Co Ltd
Hasten Biopharmaceutic Co Ltd
Hingez Therapeutics Inc
Huons Co Ltd
Ikaria Bioscience Pty Ltd
Imagine Pharma LLC
iMetabolic Biopharma Corp
Innovent Biologics Inc
Ionis Pharmaceuticals Inc
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JW Pharmaceutical Corp
Kowa Co Ltd
Kyttaro Ltd
LIB Therapeutics LLC
Lipigon Pharmaceuticals AB
LipimetiX Development Inc
Luckwel Pharmaceuticals Inc
Luye Pharma Group Ltd
Lyndra Therapeutics Inc.
MediciNova Inc
Medlab Clinical Ltd
Merck & Co Inc
Nanjing University of Science and Technology
NeuroBo Pharmaceuticals Inc
NewAmsterdam Pharma Company NV
NorthSea Therapeutics BV
Novartis AG
Novo Nordisk AS
NVP Healthcare Co Ltd
Nyrada Inc
OliPass Corporation
OrsoBio Inc
Otsuka Pharmaceutical Co Ltd
PRD Therapeutics Inc
Precision Biosciences Inc
Progenra Inc
Repair Biotechnologies Inc
Saliogen Therapeutics Inc
San Raffaele Telethon Institute for Gene Therapy
Sanegene Bio USA Inc
Sanofi
Seed Health Inc
Shandong Boan Biotechnology Co Ltd
Shanghai Henlius Biotech Inc
Shanghai Junshi Biosciences Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shifa Biomedical Corp
Sirius Therapeutics Inc
Sun Yat-sen University
Suzhou Ribo Life Sciences Co Ltd
Tangdu Hospital
Tasly Pharmaceutical Group Co Ltd
UAB Minority Health and Health Equity Research Center
Ultragenyx Pharmaceutical Inc
University Hospitals Leuven
University of Hong Kong
University of Montreal
University of Oxford
Vaxxinity Inc
Verve Therapeutics Inc
Vesicle Therapeutics Inc
Viking Therapeutics Inc
Viscera Labs Inc
Visirna Therapeutics HK Ltd
Wake Forest University
Xi'an Jiaotong University
Yaotang (Shanghai) Biotechnology Co Ltd
Zhejiang Jingxin Pharmaceutical Co Ltd
Zhejiang Teruisi Pharmaceutical Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Overview

Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Drugs Under Development by Companies

Drugs under Development by Universities/Institutes

Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Drugs under Development by Companies, 2024

Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Stage and Target, 2024

Number of Drugs by Stage and Mechanism of Action, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Projects, 2024

Discontinued Drugs, 2024

Figures

List of Figures

Number of Drugs under Development, 2024

Number of Drugs under Development by Companies, 2024

Number of Drugs under Development by Universities/Institutes, 2024

Number of Drugs by Top 10 Targets, 2024

Number of Drugs by Stage and Top 10 Targets, 2024

Number of Drugs by Top 10 Mechanism of Actions, 2024

Number of Drugs by Stage and Top 10 Mechanism of Actions, 2024

Number of Drugs by Top 10 Routes of Administration, 2024

Number of Drugs by Stage and Top 10 Routes of Administration, 2024

Number of Drugs by Top 10 Molecule Types, 2024

Number of Drugs by Stage and Top 10 Molecule Types, 2024

Frequently asked questions

Currency USD
$2,000

Can be used by individual purchaser only

Most Popular
$4,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Hypercholesterolemia reports
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Pharmaceuticals
New
Hepatocellular Carcinoma (HCC): Epidemiology Report and Forecast to 2035
$9,995 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Hypercholesterolemia – Drugs In Development, 2024 in real time.

  • Access a live Hypercholesterolemia – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more